UK markets closed

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.05+1.11 (+4.28%)
At close: 04:00PM EDT
27.05 0.00 (0.00%)
After hours: 04:20PM EDT

Beam Therapeutics Inc.

238 Main Street
9th Floor
Cambridge, MA 02142-1016
United States
857 327 8775
https://beamtx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees346

Key executives

NameTitlePayExercisedYear born
Mr. John M. Evans M.B.A.CEO & Director1.13M324.09k1978
Dr. Giuseppe Ciaramella Ph.D.President955.55k5.81M1969
Ms. Terry-Ann Burrell M.B.A.CFO & Treasurer728.2k3.06M1977
Dr. Christine P. Bellon J.D., Ph.D.Senior VP, Chief Legal Officer & Corporate Secretary680.08k437.82k1966
Dr. Amy Simon M.D.Chief Medical Officer715.58kN/A1964
Dr. Feng Zhang Ph.D.Co-FounderN/AN/AN/A
Dr. David R. Liu Ph.D.Co-FounderN/AN/AN/A
Dr. J. Keith Joung M.D., Ph.D.Co-FounderN/AN/AN/A
Dr. Manmohan Singh Ph.D.Chief Technology OfficerN/AN/AN/A
Dr. Gopi Shanker Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Corporate governance

Beam Therapeutics Inc.’s ISS governance QualityScore as of 1 July 2024 is 8. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.